Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-12-19
2006-12-19
Huff, Sheela J (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388220, C530S388730, C530S388800, C536S023530, C424S133100, C424S141100, C424S143100, C424S155100, C435S069600, C435S320100
Reexamination Certificate
active
07151164
ABSTRACT:
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.
REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4046722 (1977-09-01), Rowland
patent: 4331647 (1982-05-01), Goldenberg
patent: 4699784 (1987-10-01), Shih
patent: 4704692 (1987-11-01), Ladner
patent: 4824659 (1989-04-01), Hawthorne
patent: 4946778 (1990-08-01), Ladner
patent: 5057313 (1991-10-01), Shih
patent: 5229275 (1993-07-01), Goroff
patent: 5443953 (1995-08-01), Hansen
patent: 5530101 (1996-06-01), Queen et al.
patent: 5567610 (1996-10-01), Borrebaeck
patent: 5633425 (1997-05-01), Lonberg
patent: 5734033 (1998-03-01), Reed
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5798554 (1998-08-01), Grimaldi
patent: 5827690 (1998-10-01), Meade
patent: 6077499 (2000-06-01), Griffiths
patent: 6183744 (2001-02-01), Goldenberg
patent: 6187287 (2001-02-01), Leung
patent: 6254868 (2001-07-01), Leung
patent: 6331175 (2001-12-01), Goldenberg
patent: 2002/0004587 (2002-01-01), Miller et al.
patent: 2002/0009427 (2002-01-01), Wolin et al.
patent: 2002/0009444 (2002-01-01), Grillo-Lopez
patent: WO 88/04936 (1988-07-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 9411026 (1994-05-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/63403 (2000-10-01), None
Longo D. L. Current Opinion in Immunology, 8:353-359, 1994.
William E. Paul. Fundamental Immunology, 3rd Edition, pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Kazkaz et al. Current Opinion in Pharmacology, 4:398-402, 2004.
Gorman et al. Arthritis Research therapy, 5(Suppl 4):S17-S21, 2003.
Eisenberg et al. Clinical Immunology, 117:207-213, 2005.
Maloney et al., “New Treatments for Non-Hodgkin's Lymphoma: Monoclonal Antibodies,”Onocology(Oct. 1998), Supplement No. 8, pp. 63-76, XP 002935647, ISSN: 0030-2414.
Gopal et al., “Clinical applications of anti-CD20 antibodies,”Journal of Laboratory and Clinical Medicine(1999), vol. 134, No. 5, pp. 445-450, XP 002935646, ISSN: 022-2143.
“An Extended Primer Set for PCR Amplification of Murine Kappa Variable Regions,”Bio Techniques, Aug. 1993, vol. 15, No. 2.
Ansel, et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Fifth Edition.
Appelbaum, “Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma,”Hematology/Oncology Clinics of North America, Oct. 1991, pp. 1013-1025, vol. 5, No. 5, W.B. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia London Toronto Montreal Sydney Tokyo.
Frederick M. Ausubel, et al. (EDS.), “Current Protocols In Molecular Biology,” 1994, vol. 1, John Wiley & Sons, Inc. & Current Protocols, Published simultaneously in Canada.
Baines, et al., “Purification of Immunoglobulin G (IgG),”Methods in Molecular Biology, 1992, pp. 79-105, vol. 10, chapter 8, Immunochemical Protocols, The Humana Press, Inc., Totowa, New Jersey.
Barnes, et al., “Advances in animal cell recombinant protein production: GS-NS0 expression system,”Cytotechnology, 2000, 109-123, 32, 2000 Kluwer Academic Publishers, Netherlands.
Bird, et al., “Single chain antiboby variable regions,”Tibtech, Apr. 1991, pp. 132-137, vol. 9, Elsevier Science Publishers Ltd., United Kingdom.
Caron, et al., “ Brief Definitive Report Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies,”J. Exp. Med., Oct. 1992, pp. 1191-1195, vol. 176, The Rockefeller University Press.
Carter, et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci. USA, Immunology, May 1992, pp. 4285-4289, vol. 89.
Cochlovius, et al., “Advances in Brief Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3×CD19 Tandem Diabody, and CD28 Costimulation1,”Cancer Research, Aug. 15, 2000, pp. 4336-4341, vol. 60, Germany.
Colman, “Production of therapeutic protiens in the milk of transgenic livestock,”Biochem. Soc. Symp., pp. 141-147, 63, Portland Press, United Kingdom.
Coloma, et al., “Design and production of novel tetravalent bispecific antibodies,”Nature Biotechnology, Feb. 1997, pp. 159-163, vol. 15.
Courtenay-Luck, “Genetic manipulation of monoclonal antibodies,”Genetic manipulation of monoclonal antibodies, 1995, pp. 166-179, First published University Press, Cambridge, United Kingdom, Press Syndicate of the University of Cambridge, New York.
Devesa, et al., “Cancer Incidence and Mortality Trends Among Whites in the United States, 1947-48,”JNCI, Oct. 1987, pp. 701-770, vol. 79, No. 4, National Cancer Institute, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.
Eary, et al., “Imaging and Treatment of B-Cell Lymphoma,”The Journal of Nuclear Medicine, Aug. 1990, pp. 1257-1268, vol. 31, No. 8, The Official Publication of The Society of Nuclear Medicine, Inc.
Fitzgerald, et al., “Improved tumour targeting by disulphide stabilized diabodies expressed inPichia pastoris,” Protein Engineering, 1997, pp. 1221-1225, vol. 10, No. 10, Oxford University Press, United Kingdom.
Foon, et al., “Chronic Lymphocytic Leukemia: New Insights into Biology and Therapy,”Annals of Internal Medicine, Oct. 1, 1990, pp. 525-539, vol. 113, No. 7, Published twice monthly by the American College of Physicians.
Freedman, “Immunobiology of Chronic Lymphocytic Leukemia,”Hematology/Oncology Clinicsof North America, Apr. 1990, vol. 4, No. 2, W.B. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia London Toronto Montreal Sydney Tokyo.
Freedman, et al., “XXXVI-10 Non-Hodgkin's Lymphomas,”Cancer Medicine—Third Edition, 1993, pp. 2028-2068, vol. 2, Lea & Febiger, Philadelphia, London.
Gennaro, “Remington: Practice of,” 19thEdition,The Science and Pharmacy, 1995, Mack Publishing Company, United States.
Ghetie, et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells,” Immunology,Proc. Natl. Acad. Sci. USA, Jul. 1997, pp. 7509-7514, vol. 94, The National Academy of Sciences, USA.
Ghetie, et al., “Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin,”Blood, Mar. 1, 2001, pp. 1392-1398, vol. 97, No. 5, The American Society of Hematology, USA.
Ghetie, et al., “Evaluation of Ricin A Chain-containing Immunotoxins Directed against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents forin VivoTherapy1,”Cancer Research, 1988, pp. 2610-2617, vol. 48, No. 9.
Gillies, et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes,”Journal of Immunological Methods, 1989, pp. 191-202, vol. 125, Elsevier Science Publishers B.V. (Biomedical Division), USA.
Goldenberg, “New Developments in Monoclonal Antibodies for Cancer Detection and Therapy,”CA-A Cancer Journal for Clinicians, Jan./Feb. 1994, pp. 43-64, vol. 44, No. 1, Ortho Biotech, Inc., USA.
Goldenberg, et al., “Targeting, Dosimetry, and Radioimmunotherapy of B-Cell Lymphomas With Iodine-131-Labelled LL2 Monoclonal Antibody,”Journal of Clinical Oncology, Apr. 1991, pp. 548-564, vol. 9, No. 4, W.B. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia London Toronto Montreal Sydney Tokyo.
Goodman, et al., “The Pharmacological Basis of Therapeutics,” Fifth Edition, 1975, MacMillan Publishing Co., Inc. USA.
Goodman, et al.,
Goldenberg David M.
Hansen Hans
Qu Zhengxing
Blanchard David J.
Huff Sheela J
Immunomedics Inc.
Rossi Kimms & McDowell LLP
LandOfFree
Anti-CD20 antibodies and fusion proteins thereof and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD20 antibodies and fusion proteins thereof and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD20 antibodies and fusion proteins thereof and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3699562